Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N-dimethyl–4-(4–phenyl–1H–pyrazol–3/5–yl)−1H−pyrrole−2−carboxamide is a synthetic small molecule belonging to the phenylpyrazole class of organic compounds. It has a molecular formula of C16H16N4O and a molecular weight of approximately 280.32 g/mol[2][3][7]. The compound is experimental and not approved for clinical use in any country[2]. Its primary known biological activity is as an inhibitor of mitogen‑activated protein kinase 1 (MAPK1, also known as ERK2), with reported binding affinity (Ki) in the micromolar range[2][7]. There are no approved indications or ongoing clinical trials for this compound, and it appears to be used primarily in research settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N,N-dimethyl-4-(4-phenyl-1H-pyrazol-3-yl)-1H-pyrrole-2-carboxamide.